Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

President Donald Trump's executive order directs pharmaceutical companies to lower their prices to levels closer to those ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

The best metric is not weight, but a particularly toxic kind of fat.

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

For the first time, scientists have pitted the two most popular weight loss drugs against each other in a direct competition ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.